Junqiang Tian Selected Research

Junqiang Tian Research Topics

Disease

18	Neoplasms (Cancer) 05/2023 - 06/2008
17	Urinary Bladder Neoplasms (Bladder Cancer) 01/2024 - 06/2008
6	Prostatic Neoplasms (Prostate Cancer) 01/2024 - 09/2010
4	Short Bowel Syndrome 12/2009 - 10/2007
2	Pain (Aches) 01/2023 - 01/2020
2	Non-Muscle Invasive Bladder Neoplasms 08/2022 - 01/2021
2	Renal Cell Carcinoma (Grawitz Tumor) 01/2022 - 12/2021
2	Carcinoma (Carcinomatosis) 01/2022 - 09/2010
1	Disease Progression 01/2024
1	Chromosomal Instability (Chromosome Stability) 01/2024
1	AIDS-Related Complex (ARC) 01/2021
1	Renal Colic 01/2021
1	Nausea 01/2021
1	Dizziness (Lightheadedness) 01/2021
1	Tuberculosis (Tuberculoses) 01/2020
1	Hyperhomocysteinemia 01/2018
1	Hypoxia (Hypoxemia) 06/2012
1	Neoplasm Metastasis (Metastasis) 10/2010
1	Head and Neck Neoplasms (Head and Neck Cancer) 10/2010
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/2010

Drug/Important Bio-Agent (IBA)

4	Radiation-Sensitizing AgentsIBA 12/2013 - 09/2010
3	AndrogensIBA 01/2024 - 03/2010
3	Hormones (Hormone)IBA 01/2024 - 09/2010
3	Cisplatin (Platino)FDA LinkGeneric 11/2023 - 01/2017
3	Messenger RNA (mRNA)IBA 01/2022 - 07/2021
2	Gemcitabine FDA Link 11/2023 - 05/2023
2	RNA (Ribonucleic Acid)IBA 07/2021 - 01/2019
2	Biomarkers (Surrogate Marker)IBA 01/2021 - 10/2020
2	darinaparsinIBA 12/2013 - 06/2012
2	ArsenicIBA 12/2013 - 06/2012
2	Cytotoxins (Cytolysins)IBA 12/2013 - 06/2012
1	apalutamideIBA 01/2024
1	enzalutamideIBA 01/2024
1	Androgen Receptors (Androgen Receptor)IBA 01/2024
1	PolylysineIBA 01/2024
1	NucleotidesIBA 01/2024
1	bicalutamide (Casodex)FDA LinkGeneric 01/2024
1	Metalloproteases (Metalloproteinases)IBA 05/2023
1	DisintegrinsIBA 05/2023
1	Fibrinogen (Factor I)FDA Link 08/2022
1	6-methyladenineIBA 01/2022
1	N-methyladenosineIBA 01/2022
1	Hepatocyte Nuclear FactorsIBA 01/2022
1	Aldehyde DehydrogenaseIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Circulating Tumor DNAIBA 01/2021
1	Analgesics (Analgesic Drugs)IBA 01/2021
1	lornoxicamIBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Cadherins (E-Cadherin)IBA 01/2020
1	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2020
1	LigandsIBA 01/2020
1	CXC ChemokinesIBA 01/2020
1	Neutralizing AntibodiesIBA 01/2020
1	Oxidoreductases (Dehydrogenase)IBA 01/2018
1	HomocysteineIBA 01/2018
1	5,10-methylenetetrahydrofolic acidIBA 01/2018
1	adenovirus receptorIBA 01/2017
1	cyclobutanecarbonylcarnitine (CBCC)IBA 04/2015
1	Arsenic Trioxide (Trisenox)FDA Link 06/2012
1	IronIBA 12/2010
1	di- 2- pyridylketone- 4,4- dimethyl- 3- thiosemicarbazoneIBA 12/2010
1	Chelating AgentsIBA 12/2010
1	Integrin alphaVIBA 10/2010
1	Monoclonal AntibodiesIBA 10/2010
1	intetumumabIBA 10/2010
1	IntegrinsIBA 10/2010
1	Sodium SeleniteIBA 09/2010
1	Ascorbic Acid (Vitamin C)FDA LinkGeneric 08/2010
1	EnzymesIBA 08/2010
1	Glutathione PeroxidaseIBA 08/2010
1	CatalaseIBA 08/2010
1	Hydrogen Peroxide (Hydroperoxide)FDA LinkGeneric 08/2010
1	MetalloporphyrinsIBA 08/2010
1	PorphyrinsIBA 08/2010
1	Mn(III) 5,10,15,20- tetrakis(N- methylpyridinium- 2- yl)porphyrinIBA 08/2010
1	1-methylpyridiniumIBA 08/2010
1	MetriboloneIBA 03/2010
1	AntigensIBA 03/2010
1	Uroplakin IIIBA 03/2010
1	Flutamide (Eulexin)FDA LinkGeneric 03/2010
1	Sulfur Amino AcidsIBA 12/2009
1	Sulfhydryl Compounds (Thiols)IBA 12/2009
1	DisulfidesIBA 12/2009
1	Glutamine (L-Glutamine)FDA Link 02/2009
1	Anti-Bacterial Agents (Antibiotics)IBA 02/2009
1	CurcuminIBA 06/2008

Therapy/Procedure

5	Immunotherapy 01/2022 - 01/2019
4	Cystectomy 01/2024 - 02/2021
4	Drug Therapy (Chemotherapy) 01/2024 - 06/2008
4	Radiotherapy 01/2020 - 09/2010
3	Therapeutics 01/2024 - 01/2020
3	Aftercare (After-Treatment) 01/2023 - 10/2010
2	Urinary Diversion (Ileal Conduit) 01/2024 - 01/2023
2	Transurethral Resection of Bladder 01/2024 - 08/2022
1	Neoadjuvant Therapy 11/2023
1	Intramuscular Injections 01/2021
1	Acupuncture Therapy 01/2021
1	Operative Surgical Procedures 01/2020
1	Microbubbles 10/2010